1. Can Pharmacogenomics Prevent Disability due to Mental Illness?
Mark Faiz P.Eng.
CEO
May 29th ,2019

2. *Mental Health Roundtable Report: 2012, Statistics Canada, CAMH
Mental Illness
*15% of working Canadians are suffering from mental illness.
The cost of mental illness is approximately *$70 billion in Canada.
Disability due to mental illness accounts for *30% of prevalence but *70% of the total cost of disability in Canada
Loss of productivity, absenteeism and disability.
*Mental Health Roundtable Report: 2012, Statistics Canada, CAMH

3. Mental Health Disability Claims are a Big Issue
Sun Life Financial Group Benefits Long Term Disability approvals by diagnosis (July June 2013)

4. Diabetes *7.3% of working Canadians are suffering from diabetes.
Hardly any Canadians claim disability due to diabetes.
Canadians with diabetes respond readily to medication.
*Statistics Canada

5. What Makes Mental Illness Different?
Diabetes
Drug action not measurable
Directly measurable
Activated and cleared mainly through the liver (proper enzyme function required)
Cleared mainly by the Kidneys
Attaches to brain receptor (must have right receptor function)
Acts directly on receptors in the pancreas.
Associated with more side effects pertaining to the brain (i.e.. Mental fog, sedation, insomnia etc.)
Sometimes associated with gastrointestinal effects

6. The Challenge: Trial and Error Treatment for Patients with Mental Illness
*50% of psychiatric medications fail the first time.
Adverse reactions can be so severe, they become worse than the illness.
*Why don’t antidepressants work in some patients? 
European College of Neuropsychopharmacology (ECNP) 

7. Differential Drug Response
Patient Group
Drug NOT toxic but beneficial
Drug toxic and NOT beneficial
Same diagnosis, same prescription
Drug NOT toxic but NOT beneficial
Drug toxic but beneficial

8. Phases of Drug Actions Drug Administration- dose Absorption
Distribution
Metabolism
Elimination
Clearance
Drug + Receptor Interaction
Metabolism, Elimination
Effect (Stimulation or Inhibition)

9. Testing employees on disability in 2018
We tested 67 employees on disability due to mental disorders in 2018.
We noticed that 100% had genetic mutations that would complicate mental illness medication for them.

10. The 1000 Genome Project
An analysis of the ongoing 1000 Genome Project statistics for the genes that impact mental illness medications resulted in the following:
*40% of the population possess genetic mutations such that if they develop mental illness and need medication, they would face complexities
*1000 Genome Project 

11. Genetic Mutation Scores & Morbidity of Employees with Disability
Higher Morbidity & Genetic Mutation Score
Genetic mutation score: number of mutated genes
Baseline Morbidity score: side-effects and baseline function at home and at work based on pre-test questionnaire

12. Change in Morbidity of Employees with Disability after P3 Test
Lower Morbidity after P3 Service

13. Mental Illness related Disability in the Workforce
Out of 100% of the Canadian workforce, 40% have high genetic mutations (1)
15% suffer from mental illness(3) and many resort to medications
7.5% have NO medication problems
7.5% suffer from medication issues (4)
These most likely have high mutation scores
2-3% go on DISABILITY (5, 6)**
Genome Project & Personalized Prescription Inc. Statistics based on patient’s results*, 2. Workplace Mental Health, 2014 by Mood Disorders Society of Canada, 3. Mental Health at work report 2017, National Employee Mental Wellbeing Survey Findings 2017, Business in the Community, 4. Why Antidepressants Don't Work for Half of Patients, Live Science 2010, 5. Disability in Workplace, Statistics Canada, 6. Canadian Survey on disability, 2017, Statistics Canada ,** Calculation based on Statistics Canada reports (5, 6)

14. Can Genetics prevent Mental Illness Disability in the Workforce?
YES!

15. A Real- Life Testimonial
"I cannot say enough, it changed my life. I am so thankful for the opportunity and for what it has done for my life in a short period."- Brian Berry
Brian Berry was experiencing persistent daytime sleepiness, anxiety, and depression. His inability to function at home had cost him his marriage. His business was also affected as he was not able to keep up with his workload. He was taking multiple medications, and nothing seemed to work. At one point, he thought something more serious was going on with his health and he needed to do something about it. He spoke to Personalized Prescribing Inc. on how his life changed after the P3- Pharmacogenomic Test.

17. Scientific Team Mark Faiz, BSc. P.Eng. Feng Zhou, PhD
CEO
Sanjida Ahmed, PhD
Geneticist
Sara Temkit, PharmD
Pharmacist
Sandra Hanna, BSc. Pharm
Pharmacist
Feng Zhou, PhD
Laboratory Scientist

18. Thank You mfaiz@personalizedprescribing.com